Diabetes care: Model for the future of primary care

Posey, L. Michael; Tanzi, Maria G.

doi:10.1331/japha.2010.09112

Cited by 4 publications

(3 citation statements)

References 18 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the control group had statistically significant increase of 21.3% in this cost at the end of the study. Consequently, the pharmacist, getting integrated into the healthcare team, plays an essential role in patient pharmacotherapy, making suggestions to medical professional about drug therapy such as dose adjustments, adding or withdrawing drug(s), or both, among other actions (12,(18)(19)(20)(21). Thus, pharmacotherapeutic monitoring conducted by the pharmacist in the PC group during the period of the study contributed to encourage patient adherence to treatment, identified drug-related problems, such as adverse drug reactions, and promoted rational drug use.…”

Section: Discussionmentioning

confidence: 99%

Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service

Borges

Guidoni

Freitas

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Objective: To analyze the costs related to visits and drug prescription in outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service. Subjects and methods: A prospective and experimental study was carried out. Seventy one patients were divided into two groups: control and pharmaceutical care. Patients in the pharmaceutical care group were followed up monthly by a single clinical pharmacist. Results: The pharmaceutical care group had a statistically significant reduction in costs of metformin and emergency department visits, and increased costs with their family physicians. On the other hand, the control group had a statistically significant increase of 21.3% in the general costs of treatment and visits. Conclusion: The pharmaceutical care group maintained the same costs related to drugs and visits, while the control group showed a significant increase in general costs. Arq Bras Endocrinol Metab. 2011;55(9):686-91 Keywords Unified Healthcare System; diabetes mellitus; healthcare costs; pharmaceutical care; pharmacoeconomics RESUMO Objetivo: Analisar os custos relacionados a medicamentos e consultas em pacientes portadores de diabetes melito tipo 2 acompanhados por um programa de atenção farmacêutica. Sujeitos e métodos: Estudo prospectivo e experimental foi realizado em 71 pacientes, os quais foram divididos em dois grupos: atenção farmacêutica e controle. Os pacientes do grupo atenção farmacêutica foram acompanhados mensalmente por um farmacêutico clínico. Resultados: O grupo atenção farmacêutica apresentou redução estatisticamente significativa no custo da metformina e nas visitas de pronto atendimento e aumento no custo das consultas de atenção primária. Por outro lado, o grupo controle apresentou elevação estatisticamente significativa nos custos gerais de tratamento farmacológico e nas consultas em geral na ordem de 21,3%. Conclusão: O grupo atenção farmacêutica apresentou manutenção dos custos relacionados a consultas e medicamentos, enquanto o grupo controle apresentou aumento destes. Arq Bras Endocrinol Metab. 2011;55(9):686-91

show abstract

Section: Discussionmentioning

confidence: 99%

Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service

Borges

Guidoni

Freitas

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…The success of pharmacists in improving long‐term clinical and economic outcomes in patients with diabetes and hypertension has been well documented in several studies conducted around the country . The role of pharmacists in managing and preventing chronic disease states is expected to expand because the supply of practicing pharmacists is on the rise, whereas a shortage of 20,400 primary care physicians (PCPs) is projected by 2020 …”

mentioning

confidence: 99%

“…[3][4][5] The role of pharmacists in managing and preventing chronic disease states is expected to expand because the supply of practicing pharmacists is on the rise, whereas a shortage of 20,400 primary care physicians (PCPs) is projected by 2020. 6,7 Employer-based health plans have several incentives to improve chronic disease outcomes for their beneficiaries including improved quality of life, fewer missed days of work, and, ultimately, lower health care costs. On average, beneficiaries with diabetes have more than double the medical expenses compared with those without diabetes.…”

mentioning

confidence: 99%

Implementation and Clinical Outcomes of an Employer‐Sponsored, Pharmacist‐Provided Medication Therapy Management Program

et al. 2015

View full text Add to dashboard Cite

Our objective was to describe the implementation and clinical outcomes of an employer-sponsored, pharmacist-provided medication therapy management (MTM) program for health plan beneficiaries with diabetes mellitus and/or hypertension. We conducted a single-center retrospective medical record review. The setting was a Pharmacy MTM Clinic at a self-insured health system consisting of six hospitals and several ancillary facilities. A total of 161 health plan beneficiaries with diabetes identified during annual wellness screenings for the health plan in 2012 and 225 health plan beneficiaries with diabetes and/or hypertension identified during annual wellness screenings for the health plan in 2013 were referred to the MTM clinic based on specific criteria. In 2012 the health system expanded its existing wellness program by implementing a voluntary diabetes care program for health plan beneficiaries with uncontrolled diabetes (hemoglobin A(1c) [A1C] 7% or higher); a similar program was added for hypertension for the 2013 plan year. All participants' A1C and blood pressure results were tracked from the date of their wellness screening through the end of the plan year. The pharmacists involved had the capability to directly implement drug regimen changes according to hospital protocol or provide recommendations to the physician, as specified by the referring physician. For the 2012-2013 plan year, the mean difference in A1C from baseline to program completion was -0.38% (95% confidence interval [CI] -0.58 to -0.18%, p<0.05). For beneficiaries with a baseline A1C of 7% or higher, the mean difference was -0.69% (95% CI -0.99 to -0.39%, p<0.05). For the 2013-2014 plan year, the mean difference in A1C from baseline to program completion was -0.62% (95% CI -0.81 to -0.44%, p<0.05). In that year, the mean difference in A1C for beneficiaries with A1C 7% or higher was -0.97% (95% CI -1.23 to -0.72%, p<0.05). For those referred for hypertension, a mean difference of -13 mm Hg (95% CI -18.59 to -7.73, p<0.05) from baseline to program completion was seen in systolic blood pressure, and the mean difference in diastolic blood pressure was -7 mm Hg (95% CI -9.92 to -4.04, p<0.05). This study demonstrated that health plan beneficiaries who participated in the employer-sponsored, pharmacist-provided MTM program had significant decreases in A1C and blood pressure.

show abstract

A new data methodology to improve physician assistant research

&NA;

2011

Journal of the American Academy of Physician Assistants

View full text Add to dashboard Cite

Diabetes care: Model for the future of primary care

Cited by 4 publications

References 18 publications

Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service

Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service

Implementation and Clinical Outcomes of an Employer‐Sponsored, Pharmacist‐Provided Medication Therapy Management Program

A new data methodology to improve physician assistant research

Contact Info

Product

Resources

About